Smooth muscle-specific TMEM16A expression protects against angiotensin II-induced cerebrovascular remodeling via suppressing extracellular matrix deposition

J Mol Cell Cardiol. 2019 Sep:134:131-143. doi: 10.1016/j.yjmcc.2019.07.002. Epub 2019 Jul 10.

Abstract

Cerebrovascular remodeling is the leading factor for stroke and characterized by increased extracellular matrix deposition, migration and proliferation of vascular smooth muscle cells, and inhibition of their apoptosis. TMEM16A is an important component of Ca2+-activated Cl- channels. Previously, we showed that downregulation of TMEM16A in the basilar artery was negatively correlated with cerebrovascular remodeling during hypertension. However, it is unclear whether TMEM16A participates in angiotensin II (Ang II)-induced vascular remodeling in mice that have TMEM16A gene modification. In this study, we generated a transgenic mouse that overexpresses TMEM16A specifically in vascular smooth muscle cells. We observed that vascular remodeling in the basilar artery during Ang II-induced hypertension was significantly suppressed upon vascular smooth muscle-specific overexpression of TMEM16A relative to control mice. Specifically, we observed a large reduction in the deposition of fibronectin and collagen I. The expression of matrix metalloproteinases (MMP-2, MMP-9, and MMP-14), and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) were upregulated in the basilar artery during Ang II-induced hypertension, but this was suppressed upon overexpression of TMEM16A in blood vessels. Furthermore, TMEM16A overexpression alleviated the overactivity of the canonical TGF-β1/Smad3, and non-canonical TGF-β1/ERK and JNK pathways in the basilar artery during Ang II-induced hypertension. These in vivo results were similar to the results derived in vitro with basilar artery smooth muscle cells stimulated by Ang II. Moreover, we observed that the inhibitory effect of TMEM16A on MMPs was mediated by decreasing the activation of WNK1, which is a Cl--sensitive serine/threonine kinase. In conclusion, this study demonstrates that TMEM16A protects against cerebrovascular remodeling during hypertension by suppressing extracellular matrix deposition. We also showed that TMEM16A exerts this effect by reducing the expression of MMPs via inhibiting WNK1, and decreasing the subsequent activities of TGF-β1/Smad3, ERK, and JNK. Accordingly, our results suggest that TMEM16A may serve as a novel therapeutic target for vascular remodeling.

Keywords: Angiotensin II; Cerebrovascular remodeling; Extracellular matrix; Hypertension; MMPs; TMEM16A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Anoctamin-1 / genetics*
  • Anoctamin-1 / metabolism
  • Anoctamin-1 / physiology
  • Cells, Cultured
  • Cerebrovascular Circulation* / drug effects
  • Cerebrovascular Circulation* / genetics
  • Cytoprotection / drug effects
  • Cytoprotection / genetics
  • Down-Regulation / drug effects
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism*
  • Gene Expression / physiology
  • Hypertension / genetics
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Smooth, Vascular / metabolism*
  • Myocytes, Smooth Muscle / metabolism*
  • Organ Specificity / genetics
  • Vascular Remodeling* / drug effects
  • Vascular Remodeling* / genetics

Substances

  • ANO1 protein, mouse
  • Anoctamin-1
  • Angiotensin II